Order Center

Use the Order Center to build a Shopping Cart, view Saved Shopping Carts, Recent Orders and Quotes

SDS

Search for SDS (Safety Data Sheet) by Product Number

Oligo Ordering

Custom Products and Services, including DNA oligos (Primers and Probes), RNA, siRNA, Peptide Libraries and AQUA Peptides

Redi-Dri™ for Free-Flowing Hygroscopic Powders

Redi-Dri packaging system eliminates clumping typically noted with many hygroscopic powders and provides a free-flowing, ready-to-use material.

Contact Us

Customer Service: 0800 71 71 81
Technical Service: 0800 27 25 72
Oligo Enquiry: 0800 26 90 16

Stay Connected

Sign up for the latest product updates and promotions. For every sign-up we will plant a tree!

New Freight Charges

New standard freight charges since January 1st 2019.

Molecular Vortex - Monthly Offers

Lab Manager Sam is travelling through time and needs your help to find some special offers.

Special Offers

Seasonal offers and specific product promotions for various research topics

News & Information

Darmstadt, Germany - August 6, 2019 Merck KGaA, Darmstadt, Germany Acquires BSSN Software to Accelerate Customers’ Digital Transformation in the Lab

Merck KGaA, Darmstadt, Germany has acquired BSSN Software, a Darmstadt, Germany-based laboratory informatics company that makes data more readily accessible for ease of integration, collaboration, analysis and long-term archiving.

Read More
Darmstadt, Germany - July 24, 2019 Merck KGaA, Darmstadt, Germany to Provide BioReliance® End-to-End Solutions to Phanes Therapeutics

Merck KGaA, Darmstadt, Germany today announced the signing of a non-binding Memorandum of Understanding (MoU) with Phanes Therapeutics, Inc. (Phanes) for a collaboration on the development and manufacture of biologics for the treatment of solid tumors.

Read More
Darmstadt, Germany - July 18, 2019 Merck KGaA, Darmstadt, Germany and Broad Institute Announce CRISPR License Framework to Encourage Innovation

Merck KGaA, Darmstadt, Germany and the Broad Institute of MIT and Harvard (Boston, Massachusetts) today announced an agreement to offer non-exclusive licenses to CRISPR intellectual property (IP) under their respective control for use in commercial research and product development.

Read More